Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Poised to Hit $15.09 Billion by 2029 with Accelerating Growth Trends

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Size Growth Forecast: What to Expect by 2025?
The market for sodium glucose cotransporter 2 inhibitors has experienced robust expansion lately, projected to advance from a valuation of $10.17 billion in 2024 up to $10.96 billion by 2025, reflecting a compound annual growth rate of 7.8%. This upward trajectory during the past period stems from several key factors, including positive outcomes from initial clinical studies, an increase in the number of regulatory clearances secured, a growing incidence of diabetes diagnoses globally, and the escalating need for novel therapeutic approaches to manage diabetes.

How Will the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Size Evolve and Grow by 2029?
Anticipation surrounds the sodium glucose cotransporter 2 (sglt2) inhibitors sector, which is projected to experience vigorous expansion moving forward, reaching a market valuation of $15.09 billion by 2029, propelled by an annual growth rate (CAGR) of 8.3%; this upward trajectory is fundamentally driven by the escalating incidence of diabetes, the surge in obesity figures, heightened general awareness concerning diabetes care, and the broader utilization of these agents in addressing cardiovascular and renal ailments, while key developments shaping this timeframe encompass the incorporation of multifaceted treatment regimens, tailoring approaches to individual patients, advancements in technology, and ongoing conventional pharmaceutical research.

View the full report here:
https://www.thebusinessresearchcompany.com/report/sodium-glucose-cotransporter-2-sglt2-inhibitors-global-market-report

What Drivers Are Propelling the Growth of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market Forward?
Accelerating diabetes incidence is anticipated to boost the market for sodium glucose cotransporter 2 (SGLT2) inhibitors in the future; this condition, a collection of metabolic ailments defined by elevated blood glucose stemming from impairments in insulin production, action, or both, sees its expansion fueled by elements like increasing urbanization, heightened stress levels, exposure to environmental toxins, and inadequate access to medical care.SGLT2 inhibitors function as a therapeutic agent in diabetes management by hindering the kidney's reabsorption of glucose, consequently promoting its elimination through urine, simultaneously delivering advantages for cardiovascular and renal systems, thereby establishing them as a crucial tool for controlling the disease and its associated issues.For evidence of this trend, official figures from the Australian Bureau of Statistics in December 2023 indicated that in 2022, 5.3% of the Australian populace, equating to roughly 1.3 million individuals, had received a diabetes diagnosis, with prevalence figures closely balanced between men at 5.8% and women at 4.9%; furthermore, the frequency of diabetes consistently climbs, markedly escalating with age, where it impacts 18.7% of people aged 75 and above, with the Type 2 form being dominant, constituting 87.6% of all diagnoses; auxiliary risk factors linked to greater diabetes occurrences include emigration, residence in socioeconomically disadvantaged localities, and physical disability, all underscoring why the expanding reach of diabetes is propelling the market growth for SGLT2 inhibitors.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18473&type=smp

Which Emerging Trends Are Transforming the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market in 2025?
The key players within the sodium glucose cotransporter 2 (SGLT2) inhibitor sector are concentrating endeavors on formulating dual inhibitor therapies with the goal of achieving better results for patients and gaining greater control over glycemia. These dual inhibitor treatments involve agents that act on both sodium-glucose cotransporters, specifically SGLT1 and SGLT2, thereby boosting the effectiveness in treating ailments like diabetes and cardiac insufficiency. As an illustration, in May of 2023, the United States pharmaceutical entity, Lexicon Pharmaceuticals Inc., secured authorization from the FDA for sotagliflozin, a medication indicated for heart failure. This novel, first-of-its-kind medication, which acts as a dual SGLT1 and SGLT2 inhibitor, is administered as a daily oral tablet, with the intended purpose of lowering cardiovascular mortality, minimizing hospital admissions for heart failure, and decreasing unscheduled visits for heart failure among adults who suffer from heart failure, type 2 diabetes, chronic kidney illness, and other associated cardiovascular risks; its advantages stem from decreasing the reabsorption of glucose and sodium by the kidneys, which subsequently results in a lessening of preload and afterload alongside a reduction in sympathetic nervous system engagement.

What Are the Key Segments in the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
The sodium glucose cotransporter 2 (sglt2) inhibitorsmarket covered in this report is segmented -

1) By Type: Invokana; Jardiance; Farxiga Or Forxiga; Suglat
2) By Route Of Administration: Oral Route; Other Route Of Administration
3) By End User: Hospitals; Homecare Settings; Clinics

Subsegments:
1) By Invokana: Generic Invokana (Canagliflozin); Branded Invokana
2) By Jardiance: Generic Jardiance (Empagliflozin); Branded Jardiance
3) By Farxiga Or Forxiga: Generic Farxiga (Dapagliflozin); Branded Farxiga
4) By Suglat: Suglat (Sotagliflozin) For Diabetes; Suglat (Sotagliflozin) For Heart Failure

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=18473&type=smp

Who Are the Key Players Shaping the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market's Competitive Landscape?
Major companies operating in the sodium glucose cotransporter 2 (SGLT2) inhibitors market are Pfizer Inc., Johnson & Johnson Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Boehringer Ingelheim International GmBH, Astellas Pharma Inc, Daiichi Sankyo Company Limited, Sun Pharmaceutical Industries Ltd, Sumitomo Dainippon Pharma Co. Ltd., Taisho Pharmaceutical Holdings Co. Ltd., Lupin Limited, Glenmark pharmaceuticals, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd, Kissei Pharmaceutical Co. Ltd., Patsnap Synapse, Kotobuki Pharmaceutical Co Ltd.

What Geographic Markets Are Powering Growth in the Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors Market?
North America was the largest region in the sodium glucose cotransporter 2 (SGLT2) inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sodium glucose cotransporter 2 (SGLT2) inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18473

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.